AMANDA STEMLER: Open Payments
NPI 1427700541 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 33 payments from 10 companies in 2025. Trend: 2023 $663 · 2024 $946 · 2025 $658
Food & beverage: $658
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. | 8 | $200 |
| Astellas Pharma US Inc | 8 | $166 |
| Sumitomo Pharma America, Inc. | 4 | $87 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $53 |
| Pharmacosmos Therapeutics Inc. | 2 | $38 |
| Radius Health, Inc. | 2 | $30 |
| Exeltis, USA Inc. | 2 | $30 |
| Organon LLC | 2 | $22 |
| ABBVIE INC. | 1 | $18 |
| Amgen Inc. | 1 | $14 |
Products named: ZURZUVAE, Veozah, GEMTESA, MONOFERRIC, Tymlos, SLYND, MYFEMBREE, NEXPLANON.
Industry payments across IN — which companies pay providers there.
